Cinacalcet and achievement of the NKFK-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice - The ECHO observational study

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2852-2859

  Ureña, Pablo ^a   Jacobson, Stefan H ^b   Zitt, Emanuel ^c   Vervloet, Marc ^d   Malberti, Fabio ^e   Ashman, Neil ^f   Leavey, Sean ^g   Rix, Marianne ^h   Os, Ingrid ⁱ   Saha, Heikki ^j   Ryba, Miroslav ^k   Bencova, Veronika ^l   Baños, Ana ^m   Zani, Valter ^m   Fouque, Denis ⁿ  

^a Clinique du Landy   (France)

^b DANDERYD HOSPITAL   (Sweden)

^c Academic Teaching Hospital   (Austria)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CREMONA HOSPITAL   (Italy)

^f ROYAL LONDON HOSPITAL   (United Kingdom)

^g WATERFORD REGIONAL HOSPITAL   (Ireland)

^h Mental Health Center Glostrup   (Denmark)

ⁱ ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^j TAMPERE UNIVERSITY HOSPITAL   (Finland)

^k Krajska Nemocnice Liberec   (Czech Republic)

^l DIA NE Sro   (Slovakia)

^m AMGEN INC   (United States)

ⁿ UNIVERSITÉ LYON 1   (France)

more..

Author keywords

Calcimimetic; Cinacalcet; Clinical practice; Secondary hyperparathyroidism; Targets

Indexed keywords

CALCIUM; CINACALCET; PHOSPHORUS; SEVELAMER; STEROL; VITAMIN D; MINERAL; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE;

ADULT; ARTICLE; BONE METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; AGED; BLOOD; BONE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; EUROPE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RENAL REPLACEMENT THERAPY;

ADULT; AGED; BONE AND BONES; CALCIUM; EUROPE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MINERALS; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; VITAMIN D;

EID: 69249125715     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp144     Document Type: Article

References (23)

1. Isakova T,GutierrezO, ShahAet al. Postprandial mineralmetabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol2008; 19: 615-623
2. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999; 56(Suppl. 73): S14-S19
3. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994; 14: 219-231
4. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephro2004; 15: 2208-2218
5. Melamed ML, Eustace JA, Plantinga LC et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008; 23: 1650-1658
6. National Kidney Foundation. K/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 4): S1-S201
7. Danese MD, Belozeroff V, Smirnakis K et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1423-1429
8. Fouque D, Roth H, London G et al. Achieving K/DOQI targets for phosphorus and calcium metabolism by dialysis modality among prevalent ESRD patients in France in 2006. The French Prospective Phosphorus and Calcium Observatory in Maintenance Dialysis (Abstract). J Am Soc Nephrol 2007; 18: 9
9. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
10. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphataemia and hyperparathyroidism in dialysis patient: recommendations for a change in management. Am J Kidney Dis 2001; 37: 1331-1333
11. Moe S, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calciumphosphorus product. Am J Nephrol 2003; 23: 369-379
12. Hammerland LG, Garrett JE, Hung BCP et al. Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 1998; 53: 1083-1088
13. Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95: 4040-4045
14. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl JMed2004; 350: 1516-1525
15. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800- 807
16. Frazao JM, Holzer H, Stummvoll HK et al. Cinacalcet (Mimpara R-/Sensipar R-) maintains achievement of NKF-K/DOQI treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis (Abstract). Nephrol Dial Transplant 2005; 20 (Suppl 5): SP209
17. Martin KJ, Juppner H, Sherrand DJ et al. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCL. Kidney Int 2005; 68: 1236-1243
18. Messa P, Mac'ario F, YaqoobMet al. The OPTIMA study: assessing a newcinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36-45
19. St Peter WL, LiQ, Liu J et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 2009; 4: 354-360
20. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771
21. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
22. Henley D, Shatzen E, Lott F et al.Distribution and elimination of 45Ca after oral administration of a calcimimetic in cynomolgus monkeys under calcium loading conditions. Nephrol Dial Transplant 2007; 22(Suppl 6): 217 (abstract Sa0013)
23. Lopez I,Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307